TGFBR2 and hepatocellular carcinoma: The TGF-beta pathway analysis revealed that TGFBR2 mutations were more frequent in H/L HCC patients (2.9%) compared to NHW patients (0.4%), showing a borderline statistical significance (p = 0.07951, Table S1).